Psoriatic patients with latent tuberculosis infection and properly treated active tuberculosis need careful management when prescribing modern biological drugs. Although data and guidelines regarding tumour necrosis factor-α inhibitors advise caution and initiation of prophylactic therapy in patients with latent tuberculosis infection, the same indications do not seem to find equal force for interleukin (IL)-23 and IL-17 inhibitors. In order to evaluate the risk of reactivation in patients with latent tuberculosis infection or properly treated active tuberculosis, an observational retrospective study was conducted on the population referred to our centre [AQ1]. In the last 10 years at the clinic 19 psoriatic patients were found to be at risk of tuberculosis reactivation: 10 patients were QuantiFERON-TB-positive at baseline, 2 became positive during treatment, 6 reported prior tuberculosis infection, and 1 was QuantiFERON-TB-negative at baseline and developed disseminated tuberculosis during treatment with anti-tumour necrosis factor-α. Overall, 10.5% [AQ2] cases of active tuberculosis were observed in this group of patients; however, stratifying by biology, zero cases were observed among anti-IL-17, -13, or -12/23 over a relatively long follow-up (48.1 months).

A review of the available literature following our experience confirms the increased risk of tuberculosis reactivation with tumour necrosis factor-α inhibitors. Concerning anti-IL-23 and IL-17 drugs, available data showed high safety in patients at risk of tuberculosis reactivation. Screening of patients who should be taking IL-17 and IL-23 inhibitors is recommended for public health purposes. In case of a positive result with these therapies, consulting with an infectious diseases specialist is suggested in order to weigh up the risks and benefits of prophylactic treatment.

**Key words:** tuberculosis; infection; psoriasis; biologics.

Accepted Sep 6, 2022; Epub ahead of print Sep 6, 2022

Acta Derm Venereol 2022; 102: XX–XX.

DOI: 10.2340/actadv.v102.1982

Corr: Simone Riber, Dermatology Clinic, Department of Medical Sciences, University of Turin, via Cherasco 23, IT-10121 Turin, Italy. E-mail: simone.ribero@unito.it

Psoriasis is a chronic systemic inflammatory disease that predominantly affects the skin and joints (1). Disturbances in the innate and adaptive cutaneous immune responses are responsible for the development and sustainment of psoriatic inflammation. The inflammatory pathways involved include tumour necrosis factor (TNF)-α, interferon (IFN)-α and -β, and interleukins (ILs) -17, -12 and -23 (2). Mild and moderate forms of psoriasis may benefit from topical therapy based on steroids plus vitamin D derivatives in the first line, while, in case of poor response or increased severity, the use of systemic therapies may be considered (methotrexate, cyclosporine, dimethyl fumarate, etc.) (3, 4). Over the past 20 years, therapy with biologics has resulted in significant responses, but immune depression remains a challenge (5).

Previous contact with *Mycobacterium tuberculosis* (Mtb) exposes patients treated with biologics to an increased risk of tuberculosis (TB) reactivation. Tests for latent tuberculosis infection (LTBI) are used for identifying patients with higher odds of TB reactivation, and treatment is suggested in candidates undergoing immune suppressive treatments (6). The interpretation of either interferon-gamma release assays or tuberculin skin tests, and the sensitivity of these screening tests, is controversial (7, 8). The increased use in clinical practice of biologics in recent years and the associated risk of LTBI reactivation raise questions about the need for routine screening tests, and the possible subsequent management of LTBI patients with psoriasis (9).

Targeting different pathways, the inhibitors of TNF-α (adalimumab, infliximab, etanercept and certolizumab-pegol), of IL-12/IL-23 (ustekinumab), of IL-17 (secukinumab, ixekizumab, brodalumab) and of IL-23 (risankizumab, tildrakizumab, guselkumab) have a dif-
<table>
<thead>
<tr>
<th>No.</th>
<th>Pat. No.</th>
<th>Age, years/Sex</th>
<th>QFT status at baseline</th>
<th>Mtb status*</th>
<th>Year of ATB/QTF positivity</th>
<th>Years between ATB or QTF positivity and first biologic therapy</th>
<th>LTBI prophylaxis</th>
<th>Total number of biologic therapies after ATB or QTF positivity</th>
<th>Follow-up current biologic therapy</th>
<th>First biologic therapy after ATB or QTF positivity</th>
<th>Biologic therapy prior to/ongoing at ATB or QTF positivity</th>
<th>Previous non-biologic systemic therapy</th>
<th>Total follow-up on biologic therapy (months) after ATB or QTF positivity</th>
<th>Follow-up infectious events</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>44/F</td>
<td>Negative A</td>
<td>2017</td>
<td>3</td>
<td>Yes</td>
<td>3</td>
<td>None</td>
<td>–</td>
<td>Ixekizumab, brodalumab, risankizumab</td>
<td>Methotrexate, cyclosporine</td>
<td></td>
<td></td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>56/M</td>
<td>Positive –</td>
<td>2020</td>
<td>0</td>
<td>No</td>
<td>1</td>
<td>Risankizumab</td>
<td>12</td>
<td>Ixekizumab</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, apremilast</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>73/M</td>
<td>Negative A</td>
<td>1976</td>
<td>43</td>
<td>No</td>
<td>2</td>
<td>Risankizumab</td>
<td>8</td>
<td>Ixekizumab</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, apremilast</td>
<td>31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>81/M</td>
<td>Negative B</td>
<td>2019</td>
<td>0</td>
<td>No</td>
<td>1</td>
<td>Ixekizumab</td>
<td>28</td>
<td>Etanercept</td>
<td>Methotrexate, cyclosporine</td>
<td></td>
<td></td>
<td>28</td>
<td>QTF positivity during anti-TNF-α</td>
</tr>
<tr>
<td>5</td>
<td>53/M</td>
<td>Negative A</td>
<td>1970</td>
<td>48</td>
<td>No</td>
<td>1</td>
<td>Ixekizumab</td>
<td>30</td>
<td>Secukinumab</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, apremilast</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>51/M</td>
<td>Negative A</td>
<td>1986</td>
<td>32</td>
<td>No</td>
<td>2</td>
<td>Brodalumab</td>
<td>8</td>
<td>Secukinumab</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, apremilast</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>49/F</td>
<td>Negative B</td>
<td>2016</td>
<td>2</td>
<td>No</td>
<td>2</td>
<td>Brodalumab</td>
<td>6</td>
<td>Secukinumab</td>
<td>Methotrexate, cyclosporine</td>
<td></td>
<td></td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>58/M</td>
<td>Positive –</td>
<td>2019</td>
<td>0</td>
<td>No</td>
<td>1</td>
<td>Secukinumab</td>
<td>24</td>
<td>Etanercept</td>
<td>Methotrexate, methotrexate, acitretin</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>73/F</td>
<td>Negative A/B</td>
<td>1958</td>
<td>58</td>
<td>Yes</td>
<td>2</td>
<td>Secukinumab</td>
<td>16</td>
<td>Etanercept</td>
<td>Methotrexate, methotrexate, acitretin</td>
<td>40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>63/M</td>
<td>Positive –</td>
<td>2015</td>
<td>0</td>
<td>Yes</td>
<td>5</td>
<td>Ixekizumab</td>
<td>14</td>
<td>Adalimumab, secukinumab, etanercept, brodalumab</td>
<td>Methotrexate, cyclosporine, acitretin</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>45/F</td>
<td>Negative A</td>
<td>1984</td>
<td>34</td>
<td>No</td>
<td>2</td>
<td>Brodalumab</td>
<td>12</td>
<td>Secukinumab</td>
<td>Methotrexate, methotrexate, acitretin</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>72/M</td>
<td>Negative B</td>
<td>2010</td>
<td>0</td>
<td>Yes</td>
<td>3</td>
<td>Secukinumab</td>
<td>24</td>
<td>Etanercept, ustekinumab</td>
<td>Methotrexate, methotrexate, acitretin</td>
<td>96</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>77/M</td>
<td>Positive –</td>
<td>2019</td>
<td>0</td>
<td>Yes</td>
<td>1</td>
<td>Secukinumab</td>
<td>18</td>
<td>–</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, etanercept</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>56/M</td>
<td>Positive –</td>
<td>2020</td>
<td>0</td>
<td>No</td>
<td>1</td>
<td>Brodalumab</td>
<td>16</td>
<td>Etanercept, ustekinumab, infliximab</td>
<td>Methotrexate, cyclosporine, acitretin</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>64/M</td>
<td>Positive –</td>
<td>2010</td>
<td>0</td>
<td>No</td>
<td>4</td>
<td>Secukinumab</td>
<td>28</td>
<td>Etanercept, ustekinumab, infliximab</td>
<td>Methotrexate, cyclosporine, acitretin</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>74/M</td>
<td>Positive –</td>
<td>2011</td>
<td>0</td>
<td>Yes</td>
<td>2</td>
<td>Ixekizumab</td>
<td>30</td>
<td>Etanercept</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, etanercept</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>55/M</td>
<td>Positive –</td>
<td>2010</td>
<td>0</td>
<td>Yes</td>
<td>2</td>
<td>Ixekizumab</td>
<td>24</td>
<td>Etanercept</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, etanercept</td>
<td>120</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>55/F</td>
<td>Positive –</td>
<td>2016</td>
<td>1</td>
<td>Yes</td>
<td>2</td>
<td>Ustekinumab</td>
<td>30</td>
<td>Secukinumab</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, etanercept</td>
<td>42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>80/M</td>
<td>Positive –</td>
<td>2018</td>
<td>0,25</td>
<td>Yes</td>
<td>1</td>
<td>Secukinumab</td>
<td>32</td>
<td>–</td>
<td>Methotrexate, methotrexate, cyclosporine, acitretin, etanercept</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

M: male; F: female; TNF-α: tumour necrosis factor alpha; LTBI: latent tuberculosis infection.
ferential impact on risk of LTBI reactivation (7). Clinical practice and the screening test for biologics in psoriasis was originally based on adalimumab, and then applied to the other anti-ILs, but currently it seems more appropriate to differentiate this approach according to the effective drug-associated risk.

This paper summarizes the most recent immunological and clinical evidence on the role of biologics and their safety with regards to Mtb infection, including the clinical experience of our tertiary referral centre, the Dermatology Clinic of the University of Turin, Turin, Italy.

METHODS

An observational retrospective study was performed. Inclusion criteria were: all adult patients who underwent treatment with any approved biologics for moderate-to-severe psoriasis from January 2010 to November 2021 at the Dermatology Clinic of Turin University Hospital; patients presenting a positive screening QuantiFERON-TB (QTF) Gold [AQ5] test with no evidence of active tuberculosis (ATB) (negative chest X-ray, no compatible signs and symptoms); patients considered at high risk of reactivation and labelled as LTBI; or a prior history of properly treated active tuberculosis (pATB) with or without a positive screening QTF, or a negative pre-biologics QTF with subsequent development of a positive QTF or ATB under treatment.

Demographic and clinical data were recorded. The study was approved by the ethics committee of Turin University hospital (IT10771180014 SS-Dermo20).

RESULTS

A total of 540 patients with moderate-to-severe psoriasis were followed in our clinic [AQ1] from November 2011 to November 2021. Of these, 19 patients met the inclusion criteria. The patients’ characteristics are summarized in Table I.

Six patients had pATB: 5 developed TB during their youth, and 1 patient developed TB 2 years before the first biologic therapy, during the screening for systemic therapy for psoriasis. The mean time from pATB to the start of the first biologics was 36.3 years (range 3–58 years). According to the clinical records all these patients had negative QTF at first biologic prescription.

One case of TB reactivation occurred in the pATB group. A male patient who experienced pATB 58 years previously developed TB reactivation after 24 months on etanercept, despite commencing isoniazid prophylaxis 1 month prior to starting treatment with biologics. He stopped etanercept, underwent appropriate anti-tubercular treatment and was switched to secukinumab with complete response of his psoriasis after 16 months without any further reactivation.

One female subject with baseline-negative QTF developed disseminated TB after 2 months of adalimumab and 10 months of etanercept.

Ten patients had a positive QTF at the baseline screening for the first biologic prescription (10 subjects). Among them, biologics were started after a mean time of 1.5 months, 8 patients started the treatment immediately after positive QTF, 1 patient after 3 months, and 1 after 12 months from the positive result. No patients in the positive QTF group experienced TB reactivation.

Two patients had positive QTF during follow-up while under anti-TNF-α treatment (1 patient on adalimumab and 1 on etanercept) after a negative baseline.

Overall, 9 patients underwent treatment for LTBI before administration of biologics: 7 in the QTF group and 2 in ATB. As for the latter, these 2 patients were deemed at high risk of reactivation despite previous treatment, as they were not able to precisely recall drugs and duration of previous anti-tubercular treatment, and after infectious disease consultation they underwent prophylaxis. Nine of the 10 patients without prophylactic treatment received only anti-IL17 or anti-IL-23 biological treatments, while 1 patient with positive QTF did not receive prophylaxis, due to concomitant severe liver disease. Infectious disease consultation deemed hepatotoxicity to overcome the risk of LTBI reactivation despite the indication to start infliximab and etanercept; no LTBI reactivation was observed during and after the overall 24 months under TNF-α.

The mean follow-up time under psoriatic biologic therapy was 48.1 months ([AQ6] 12–120). Sixteen patients had a regular follow-up. One patient is not currently taking biological therapy for psoriasis due to multiple failures after brodalumab, ixekizumab, and risankizumab. Eighteen patients are currently on biologics, 6 of whom are on secukinumab, 4 on brodalumab, 5 on ixekizumab, 2 on risankizumab, and 1 on ustekinumab. The mean follow-up duration under each biologic is reported in Table II.

Overall, 2/19 (10.5%) cases of ATB were observed in this group of patients at increased risk of LTBI reactivation based on previous ATB history or positive screening; nevertheless, when stratified by biologics, zero cases were observed among patients treated with anti-IL-17, -IL-13, or -IL-12/23 on a relatively long follow-up.

DISCUSSION

Biology of latent tuberculosis infection

LTBI should be considered as a dynamic spectrum of conditions that depend on mycobacteria burden and

<table>
<thead>
<tr>
<th>Type of biological therapy</th>
<th>Mean follow-up, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risankizumab</td>
<td>9.3</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>21.6</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>23.6</td>
</tr>
<tr>
<td>Brodalumab</td>
<td>10.3</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>28</td>
</tr>
<tr>
<td>Etanercept</td>
<td>53</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>11</td>
</tr>
<tr>
<td>Infliximab</td>
<td>21</td>
</tr>
</tbody>
</table>
replication as well as on hosts’ inflammatory status and immune system efficacy (10, 11). Reactivation may even occur asymptptomatically, and spontaneously return to a deeper pathologically latency. Mechanisms that allow progression from latency to clinical manifestations are unclear (10, 11).

Granulomas represent the immunological and mechanical barrier to control Mt. Maintenance of granulomas is a dynamic process involving changes in CD4+ and CD8+ T-cells, B-cells, macrophages, neutrophils, fibroblasts, and multinucleated giant cells (11). Several cytokines, including TNF-α, IL-12/IL-23 and IL-17 (Table S1). [AQ7] Adaptive immunity to Mt depends mainly on CD4+ T-cells, the major producers of IFN-γ, contributors of TNF-α production, and regulators of optimal CD8+ T-cells functioning (11, 12).

Anti-TNF-α therapy can have a negative impact on the long-lasting maintenance of granuloma integrity, on TNF-α-induced macrophages apoptosis, and on the enhanced intracellular killing of Mt (12–14). The IL-12 family (including IL-12 and IL-23) and IL-17 pathway are involved during early protective responses and in boosting vaccine-induced immunity.

In early infections, IL-12p70 (IL-12p35/p40) triggers dendritic cells, promotes macrophage migration, induces IFN-γ production from CD4+ and NK cells, and the differentiation of Th1 effectors (15). IL-23 (IL-23p40/p19) induces the differentiation of Th17 cells, associated with MTb protection during primary infection, and plays a secondary role to IL-12 in inducing IFN-γ-mediated responses (16), genetic defects in IL-12/IL-23/IFN-γ axis have been associated with severe and disseminated disease (17), but also that IL-12/IL-23-deficient mice have been found more susceptible to Mt than IL-12-deficient mice (18), and that IL-23-deficient mice have shown normal protective immunity and mycobacterial burden (15, 19). [AQ8]

IL-17 is an inflammatory cytokine capable of inducing chemokine gradients and initiating inflammation, especially in mucosal tissues (16). While IL-17 seems beneficial during primary Mt infection, it may become detrimental during chronic infection (11, 13, 15, 16). IL-17 appears to favour the control of tuberculous granuloma in human models by increasing specific tissue-resident memory T-cells (CD4+ and CD8+) (20).

A schematic representation of the comparison in LTBI reactivation risk between TNF-α, IL-12/IL-23, and IL-17 pathway blockades is shown in Fig. 1.

**Literature review of clinical data**

Interpretation of the currently available data is difficult due to the differentiation in the various studies between tuberculous reactivation, new tuberculous infection, and positive tests, such as tuberculin skin test (TST) and IFN-gamma releasing essay (IGRA, i.e. QuantiferonTB) after negative baseline screening. The different epidemiological risk within the European area and the variable sensitivity of current screenings, and their interpretation, further complicate the risk assessment of TB reactivation in psoriatic patients treated with biologics (9). The percentage of psoriatic patients with LTBI in Europe is approximately 20%, while in Italy this incidence has been reported to be lower (8.2%) (21).

Recent European guidelines recommend Mt screening according to local regulations (7). The screening should be based on the patient’s personal history, physical examination, chest X-ray, and laboratory tests, such as TST and IGRA; the guidelines also recommend repeated screening during treatment. Different types of prophylaxis are available for LTBI: isoniazid for 6 months, isoniazid+rifampin for 3 months, or rifampin alone for 3–4 months, all associated with an 85–95% reduction in the risk of TB reactivation (7, 22).

With methotrexate, an increased risk of tubercular reactivation is evidenced (23). The frequent use of this treatment before initiation of biological therapy may cause confusion regarding which drugs cause LTBI reactivation. Of the patients in this study, 73.6% were treated with methotrexate before biologics, and both cases that developed ATB belonged to this group.

**Tumour necrosis factor-α inhibitors**

The European guidelines advise against the use of anti-TNF-α in patients with LTBI. In this type of patient, systemic treatment with retinoids and dimethyl fumarate, and biological drugs based on IL-17 and IL-23, are suggested (7). The risk of TB reactivation in psoriatic patients treated with anti-TNF-α is ascertained from several clinical trials and real-world evidence, in particular adalimumab and infliximab (and less strongly for etanercept) (24). A review conducted in 2013 on 13 clinical trials conducted from 2003 to 2012 on psoriatic patients on anti-TNF-α showed 6 cases of TB reactivation out of 3,657 total patients, 1 case with adalimumab and 5 with infliximab (5). Souto et al. highlighted an OR [AQ9] of 1.91, with 31 case of TB under TNF inhibitors for immune-mediated disease (25). Minozzi et al. conducted a systematic review encompassing data from 71 published randomized controlled trials (RCTs) involving 22,760 adult patients with a rheumatological disease treated with anti-TNF-α, and from 7 OLE [AQ9] studies with 2,236 patients highlighting an increase in the occurrence of TB (250%) associated with anti-TNF drug use (26). ATB was recently reported in a patient receiving certolizumab-pegol treatment (27, 28).

Tuberculous screening before starting biological treatment does not always correctly identify patients who are at risk of reactivation (8). Numerous cases, even fatal cases, of tuberculous reactivation in patients with...
negative screening, are reported in the literature (29). Similarly, positive QTF results after negative baseline during treatment with biologics appear to be difficult to evaluate. A retrospective study reported positive QTF of 6.5% after negative baseline screening in 526 patients treated with anti-TNF, anti-IL-17, and anti-IL-12/23 (21, 30). In the current population 2 patients experienced QTF conversion during treatment with anti-TNF-α and ustekinumab. A female patient from the current population developed disseminated TB with involvement of the brain, liver, and bones, after negative QTF screening and treatment with etanercept and adalimumab; in this case the clinical history strongly oriented towards a case of reactivation rather than a primary Mtb infection. Recent evidence confirms low risk of reactivation in LTBI patients under anti-TNF-α treatment for psoriasis after prophylactic treatment (31, 32). Nevertheless, cases of LTBI reactivation in patients who received prophylaxis have also been described (33, 34). In the current series, a patient who had ATB almost 60 years earlier, and despite adequate prophylaxis, experienced reactivation of pulmonary TB after 2 years of etanercept-based therapy.

**Interleukin-12/interleukin-23 inhibitors**

Ustekinumab is not traditionally considered to increase the risk of tuberculous reactivation, although preclinical studies attribute a major role to IL-12, and to a lesser extent IL-23, in controlling TB infection (35). A recent Korean study showed an incidence of TB in the population treated with ustekinumab comparable with that of the general population (35). To our knowledge, 10 cases of tuberculous reactivation after therapy with ustekinumab are reported in the literature, and of similar size is the population that experienced QTF conversion during the treatment (21, 25, 36–39). In our series, 3 patients were
treated with ustekinumab for a median follow-up of 28 months; 2 underwent prophylactic treatment, and no case of LTBI reactivation occurred.

**Interleukin-17 inhibitors**

Regarding secukinumab, out of 7,355 patients in phase I, II, III trials, 132 patients had LTBI or reported pATB, 107 underwent prophylactic therapy, and 25 patients with pATB that resulted negative to screening received secukinumab without anti-TB treatment. No case of reactivation was observed (40). An Italian real-life study on 12 patients with LTBI showed no reactivation on secukinumab without previous prophylactic treatment after a 52-week follow-up (6). Further real-life studies have reported regular follow-up in LTBI patients treated with secukinumab without prophylactic therapy, despite 10 cases of QTF positivity during treatment (21, 41, 42). In the current series, 11 patients have taken secukinumab, and 6 are still currently on it. Four patients did not receive prophylactic treatments, 2 of these had negative screening, but pATB, while 1 received anti-tubercular treatment before starting secukinumab due to disseminated TB. Overall, the mean follow-up was 23.6 months with no cases of LTBI reactivation. In line with previous results, the current data do not suggest an increased risk of developing TB or reactivation in patients treated with secukinumab, despite significant exposure to Mtb.

Unlike secukinumab, the phase I, II, and III studies of ixekizumab and brodalumab excluded LTBI-positive patients at screening. Regarding ixekizumab, out of 7,016 patients being treated for psoriasis, 133 patients experienced emergent LTBI, 48 remained on treatment and 11 did not receive anti-TB treatment, and 9 discontinued the treatment. [AQ10] No cases of reactivation were reported. Five-year follow-up data in UNCOVER-1 and -2 studies in 206 patients (43). [AQ11]

Regarding brodalumab, in 4,464 patients in phase I, II, III studies, no cases of reactivation were reported. An extension study on 129 patients at 108 weeks also reported no cases of reactivation (44).

The current series is the first to report real-life data on ixekizumab and brodalumab in psoriatic patients at risk of tuberculous reactivation. Seven patients were treated with ixekizumab for a mean follow-up of 21.6 months without reactivation. Three out of 7 patients did not receive prophylactic treatment, 2 due to pATB at a young age with negative screening, and 1 patient because ixekizumab was not deemed [AQ12] at risk of reactivation.

Six patients received brodalumab for a mean follow-up of 10.3 months without reactivation.

**Interleukin-23 inhibitors**

In phase II and III trials on IL-23-inhibitors, 105 psoriatic patients with LTBI on guselkumab did not report reactivation (40).

From the phase I, II, and III studies of risankizumab for psoriasis, 72 patients tested positive for LTBI and received prophylactic therapy, with no cases of reactivation (40). Thirty-one patients who tested positive for LTBI in the IMMhance study did not receive prophylactic therapy without reactivation cases at 55 weeks [AQ13]. Overall, no cases of reactivation were reported in studies involving 2,673 treated patients (40, 45).

Two patients with pATB and 1 with positive QTF received risankizumab in our clinic. Only 1 patient with pATB underwent prophylaxis; in consideration of the absence of cases of reactivations in the literature, prophylaxis was not given in the other patients. After an average of [AQ14] 9.3 months of follow-up, no cases of tuberculous reactivation occurred. To date, the current data are the only real-life experience of risankizumab in patients at risk of LTBI reactivation.

**Final considerations**

Concerning the anti IL-23 and IL-17 drugs, the data in the literature show high safety in patients with LTBI and previous ATB, and data are also available from patients at risk who did not receive prophylactic therapy without proof of reactivation. Seven cases of de novo ATB, thus considered unrelated to treatments, are reported in these classes (5 secukinumab, 1 tildrakizumab, and 1 ixekizumab) (40). In the current study population, irrespective of a positive history of LTBI and ATB and possible prophylactic therapy, no cases of reactivation occurred during treatment with brodalumab, secukinumab, ixekizumab, and risankizumab.

In the light of this emerging evidence, after an initial risk assessment using QTF, in the event of a positive result, anti-IL-23 or anti-IL-17 drugs are prescribed without starting prophylactic therapy, but patients are still referred and linked to infectious disease or pneumologist care and consultation. Indeed, as for other autoimmune disorders (46), there is controversial evidence (47–50) and plausible biological explanations (51, 52) of an increased risk of TB even in biologic-naïve patients with psoriasis., we do not endorse an abrupt cessation of TB screening before and during any type of biologics in psoriatic patients. Rather, we suggest preserving this strategy from a broader public health point of view, waiting for cost-effectiveness analysis and an in-depth assessment of TB vs prophylaxis risks in biologic-naïve patients, as well as in the trajectory of primary Mtb infections during blockade of IL-12, IL-23 and IL-17 pathways. Indeed, if a first line has to be started with these inhibitors, the physician may not wait for TB screening results before administering the treatment. In case of a positive screening, an infectious disease consultation will balance the risks and benefits and the urgency of eventual anti-tuberculous prophylaxis.
Conclusion

Despite in-depth experience with biologics in the treatment of psoriasis, there are still several controversial data on the assessment and quantification of the risk of tuberculous reactivation. The current data fit with the emerging evidence on the safety of IL-12/IL-23, IL-23 and IL-17 inhibitors in terms of LTBI reactivation, and add preliminary evidence for newer drugs with as-yet no observational data. While these findings endorse the idea that Mtb screening could be no more mandatory [AQ15] before starting anti-IL-12/IL-23, -IL-23 or -IL-17 therapy, important caveats remain to be discussed and a consensus needs to be reached on the usefulness and interpretation of Mtb screening in this population of patients.

ACKNOWLEDGEMENTS

The study was approved by the ethics committee of Turin University Hospital (21071180014 SS- Dermo20), and was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study. Data are available from the corresponding author upon reasonable request.

The authors have no conflicts of interest to declare.

REFERENCES

L. Mastorino et al. “Psoriasis and risk of TB reactivation in biologic drug therapy”

867–875.


47. Bassukas ID, Kosmidou M, Gaitanis G, Tsiouris A, Tsianos E. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease. Acta Derm Venereol 2011; 91: 444–446.


Dear Author,

Some questions have arisen during the preparation of your manuscript for typesetting. These are marked in the text by [AQ#]. Please consider the points below and make any corrections required.

**AQ:** For clarity, state the name and location of the centre/clinic.

**AQ2:** Please make sense clear. Do you mean: “Overall, 10.5% of this group of patients developed active tuberculosis; however, stratifying by biologic therapy, zero cases were observed among patients treated with anti-IL-17, -13, or -12/23 over a relatively long follow-up (48.1 months).”?

**AQ3:** Is quantiferon a trade name? If so, please state the name and location of the manufacturer. Also check consistency of capitalization vs the Abstract and other mentions in the text.

**AQ4:** Taeniasis?

**AQ5:** Give name and location of manufacturer.

**AQ6:** What are these numbers?

**AQ7:** Incomplete sentence – please check sense.

**AQ8:** Long sentence – sense unclear. Do you mean: “IL-23 (IL-23p40/p19) induces the differentiation of Th17 cells, associated with MTb protection during primary infection, and plays a secondary role to IL-12 in inducing IFN-γ-mediated responses (16). Genetic defects in IL-12/IL-23/IFN-γ axis have been associated with severe and disseminated disease (17), IL-12/IL-23- deficient mice have been found to be more susceptible to Mt than IL-12-deficient mice (18), and IL-23- deficient mice have shown normal protective immunity and mycobacterial burden (15, 19).”?

**AQ9:** Expand abbreviation.

**AQ10:** Check punctuation for sense. Do you mean: “Regarding ixekizumab, out of 7,016 patients being treated for psoriasis, 133 experienced emergent LTBI, 48 remained on treatment, 11 did not receive anti-TB treatment, and 9 discontinued treatment.”?

**AQ11:** Incomplete sentence.

**AQ12:** Insert “to be associated with risk of...”?

**AQ13:** Sense? Please check and rewrite this sentence.

**AQ14:** “a mean of”?

**AQ15:** Do you mean “… may no longer be mandatory…”?

**AQ16:** Is this a copyright statement? If a reference, please move to the reference list and number it sequentially. If a statement of copyright, please check wording with the Editorial Office – e.g. “Reproduced from..... with permission”.

Many thanks.
Table SI. Monoclonal antibodies for psoriasis and psoriatic arthritis: indications, biological mechanisms and risk in latent tuberculosis infection (LTBI)

<table>
<thead>
<tr>
<th>Monoclonal antibody</th>
<th>Target</th>
<th>Indication for psoriasis/psoriatic arthritis</th>
<th>Main known immune mechanisms in LTBI</th>
<th>Main cellular source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Certolizumab pegol</td>
<td>TNF-α</td>
<td>Y/Y</td>
<td>Macrophages turn-over and reduced Mtb burden (inducer of cell apoptosis)</td>
<td>Th1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Enhancing intracellular Mtb killing</td>
<td>CD8+ T-cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Turn-over and maturation of cells constituting granulomas (maintenance of granuloma integrity)</td>
<td>Macrophages</td>
</tr>
<tr>
<td>Etanercept</td>
<td>TNF-α</td>
<td>Y/Y</td>
<td>Differentiation and survival of Mtb-specific CD4+ effector and memory cells</td>
<td>Macrophages</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IFN-γ-mediated response</td>
<td>APC (as ex. dendritic cells)</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>TNF-α</td>
<td>Y/Y</td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td>Infliximab</td>
<td>TNF-α</td>
<td>Y/Y</td>
<td>IFN-γ-mediated response</td>
<td></td>
</tr>
<tr>
<td>Golimumab</td>
<td>TNF-α</td>
<td>N/Y</td>
<td>IFN-γ-mediated response</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>IL-12p40</td>
<td>Y/Y</td>
<td>Differentiation of Th17</td>
<td>Th1</td>
</tr>
<tr>
<td></td>
<td>IL-23p40</td>
<td></td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td>Gusekumab</td>
<td>IL-17A</td>
<td>Y/Y</td>
<td>IFN-γ-mediated response</td>
<td>Th1</td>
</tr>
<tr>
<td>Tildrakizumab</td>
<td>IL-23p19</td>
<td>Y/N</td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td>Risankizumab</td>
<td>IL-23p19</td>
<td>Y/N</td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td>Secukinumab</td>
<td>IL-17A</td>
<td>Y/Y</td>
<td>Differentiation of Th17</td>
<td>Th1</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>IL-17A</td>
<td>Y/Y</td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IL-17A/F</td>
<td></td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
<tr>
<td>Brodalumab</td>
<td>IL-17A</td>
<td>Y/N</td>
<td>Differentiation of Th17</td>
<td></td>
</tr>
</tbody>
</table>

OR: odds ratio; Mtb: Mycobacterium tuberculosis complex; Th1: CD4+ T-helper 1 lymphocytes; APC: antigen-presenting cells; Th17: CD4+ T-helper 17 lymphocytes; iNKT: invariant natural killer T-cells; TNF-α: tumour necrosis factor alpha; LTBI: latent tuberculosis infection; Y: yes; N: no.